Please login to the form below
job losses
This page shows the latest job losses news and features for those working in and with pharma, biotech and healthcare.
MSD hangs ‘for sale’ sign on French facility, shedding 207 staff
Job losses will be across manufacturing and R&D divisions. Merck &Co/MSD has set another part of its ongoing cost-cutting drive in motion, announcing the closure of a plant ... in France that will result in 207 job losses across manufacturing and R&D.
Latest news
-
Amgen exits neuroscience R&D to focus on growth areas
The latter projects will be taken over by its inflammation research teams, said Amgen, with the job losses expected to hit the hardest at its R&D facilities in Cambridge, Massachusetts,
-
Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
Company says decision is not related to Brexit
-
Mereo’s shareholders back OncoMed takeover
That prompted a cull of the pipeline and big job losses, with OncoMed focusing its energies on early-stage candidates navicixizumab, etigilimab and OMP-336b11 for solid tumours, plus a fourth
-
WPP to cut 3,500 jobs in major restructuring
The company hasn't yet made clear how the plans will affect WPP Health and Wellness, which has a large number of pharma and consumer health clients, but job losses and
-
GSK and Pfizer to create combined consumer health titan
It thinks it can carve £500m off its costs by 2022, and says that some job losses are expected.
More from news
Approximately 1 fully matching, plus 71 partially matching documents found.
Latest Intelligence
-
Creating a 21st century life sciences ecosystem
Brain drain. Since Freeman became an MP in 2010 there have been thousands of job losses across the UK as a number of companies, including GSK, Novartis, AstraZeneca and most notably
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Three strategies for managing loss of exclusivity successfully
Patent losses could sink Allergan”. 1. “Drug prices to plummet in wave of expiring patents”. ... 4. It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug manufacturers – shrouded in the threat
-
Three strategies for managing loss of exclusivity successfully
Patent losses could sink Allergan”. “Drug prices to plummet in wave of expiring patents”. ... It’s no wonder “loss of exclusivity (LOE)” or “the patent cliff” is an ominous prospect for drug manufacturers – shrouded in the threat of job
-
Artificial Intelligence in healthcare
However, AI is not without its critics, with concerns including job losses where human input is no longer required, or sometimes involve deeper concerns as to the ethics intrinsic to AI. ... As mentioned earlier, job losses are also a concern. Media
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- Takeda’s dengue vaccine receives MHRA approval for those aged four years and older
- Sandoz’s biosimilar denosumab application accepted by FDA for osteoporosis
- Novartis’ Cosentyx shows continued improvement in hidradenitis suppurativa patients
- NHS urges people yet to receive their COVID-19 booster to come forward
- Biosimilars and beyond: innovating for improved patient outcomes
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Why female mentorship is so powerful in pharma
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- Europe’s cancer community publishes new report on transforming patient care
- Digital technology: a significant change in healthcare innovation
- Assessing the value of interim analyses in clinical trials
PMHub
Wisepress
Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...
Latest intelligence
- Biosimilars and beyond: innovating for improved patient outcomes
- How Europe’s biosimilar landscape has rapidly evolved over the last two decades, bringing biological medicines to more patients than ever before...
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
